These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1006 related articles for article (PubMed ID: 25418708)

  • 61. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.
    Raal F; Schamroth C; Patel J; Becker P
    Cardiovasc J Afr; 2007; 18(5):325-9. PubMed ID: 17985033
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cholesterol treatment and changes in guidelines in an academic medical practice.
    Schoen MW; Salas J; Scherrer JF; Buckhold FR
    Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
    [TBL] [Abstract][Full Text] [Related]  

  • 64. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
    Atherosclerosis; 2015 Aug; 241(2):450-4. PubMed ID: 26074319
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients.
    Xanthopoulou I; Davlouros P; Siahos S; Perperis A; Zaharioglou E; Alexopoulos D
    Lipids Health Dis; 2013 Nov; 12():170. PubMed ID: 24209409
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
    Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
    Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
    Tokgözoğlu L; Casula M; Pirillo A; Catapano AL
    Atheroscler Suppl; 2020 Dec; 42():e1-e5. PubMed ID: 33589218
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dyslipidaemia management in the cardiac rehabilitation clinic of a tertiary referral centre: analysis of the impact of new ESC guidance on LDL-C target achievement.
    McCaughey C; Ranganathan D; Kerins M; Murphy G; Murphy R
    Ir J Med Sci; 2022 Dec; 191(6):2569-2577. PubMed ID: 35031936
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2.
    Sulman D; Zeitouni M; Silvain J; Kerneis M; Guedeney P; Barthélémy O; Brugier D; Sabouret P; Lattuca B; Mertens E; Posson J; Procopi N; Salloum T; Collet JP; Montalescot G
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):633-643. PubMed ID: 35381063
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
    Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
    Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.
    Levy ME; Greenberg AE; Magnus M; Younes N; Castel A
    AIDS Patient Care STDS; 2018 Feb; 32(2):58-69. PubMed ID: 29561173
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort.
    Schonmann Y; Bleich O; Matalon A; Yeshua H
    Eur J Prev Cardiol; 2018 May; 25(8):870-880. PubMed ID: 29517367
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.